ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

N4P N4 Pharma Plc

0.80
-0.025 (-3.03%)
Last Updated: 10:33:59
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
N4 Pharma Plc LSE:N4P London Ordinary Share GB00BYW8QM32 ORD 0.4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.025 -3.03% 0.80 0.75 0.85 0.825 0.80 0.83 501,502 10:33:59
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Drug & Proprietary Stores 0 -1.03M -0.0057 -1.40 1.45M
N4 Pharma Plc is listed in the Drug & Proprietary Stores sector of the London Stock Exchange with ticker N4P. The last closing price for N4 Pharma was 0.83p. Over the last year, N4 Pharma shares have traded in a share price range of 0.625p to 2.175p.

N4 Pharma currently has 181,080,349 shares in issue. The market capitalisation of N4 Pharma is £1.45 million. N4 Pharma has a price to earnings ratio (PE ratio) of -1.40.

N4 Pharma Share Discussion Threads

Showing 5376 to 5397 of 8600 messages
Chat Pages: Latest  224  223  222  221  220  219  218  217  216  215  214  213  Older
DateSubjectAuthorDiscuss
11/1/2019
16:28
Just looking back in here, the chart is looking very much like it's ready for another leg up IMO... what likely news is coming up, please? Ta.
cyberbub
09/1/2019
12:15
that is a lotta cash
remarkomsoc
09/1/2019
12:04
In 2019, Moderna expects to start its first clinical trial on an mRNA therapy for a rare disease and expand its work in cancer, milestones Bancel expects to change the conversation around the company.

So why aren’t investors buying into the vision?

“You need to ask them,” Bancel said with a laugh, adding that Moderna’s complexity — it has 11 projects in human trials and 10 more waiting in the wings — might be befuddling to outsiders.

But investors who spoke to STAT pointed to two sticking points: Moderna is yet to rule out the lingering risks tied to mRNA, and, even at its depressed valuation, the company is simply too expensive.

Regardless of its short-term stock price, the post-IPO Moderna is sitting on $1.7 billion of cash, a sum that gives it at least three years of runway to change minds on Wall Street.

remarkomsoc
08/1/2019
00:10
Anyone still here?
jimbobaroony
05/1/2019
11:41
N4P ripe for a 9 billion dollar takeover:)))
ch1rp
04/1/2019
15:03
Celgene deal a ‘catalyst’ for pharma takeovers
cf456
31/12/2018
14:48
Aim chaos are totally biased
jimbobaroony
31/12/2018
13:17
That #N4P is down at this share price after the developments since the folding of the reform. div. is incredible. I also think we're in for a monster Q1, and indeed a monster 2019. January - details of MedImmune collaboration, I'm guessing. Not sure why more aren't positioning for this!Aim Chaos tweeting on 27/12/18
ch1rp
24/12/2018
07:58
Merry Christmas all N4P users. Here's to a wonderful 2019 and to successful AZ trials:)))
ch1rp
21/12/2018
08:24
Good start. Was a bit oversold late on yesterday
dave4545
20/12/2018
15:52
hmm, feels like they're "tidying things up", for a takeover?
remarkomsoc
20/12/2018
15:47
Actual clinical progress with the product they already have would be welcome.
jimbobaroony
20/12/2018
08:18
N/T to buy now at 10.2p

Not everything will fall today, some stocks will get chased up and N4P might
be one of them

dave4545
20/12/2018
08:17
Great new will now fly
thomstar
20/12/2018
08:01
"Previously, the Company had a licence to pursue the use of nucleic acids in all human therapeutic treatments, with an option to extend its licence to additional fields such as animal vaccines, peptides and small molecules. Under the extended terms of the Licence Agreement, the Company now has an exclusive global licence for the commercialisation of Nuvec® in all these areas, as well as other possible commercial applications, such as dual therapy cancer treatments."The company have always had rock solid patents. They can now explore more fully the use of nuvec in all kinds of applications. Well done N4:)))
ch1rp
20/12/2018
07:58
Some knew that news was coming.
dave4545
19/12/2018
14:02
Moving a bit now though Nobby

Always been a great trading stock.

Breaks 10p and 12p is on again

dave4545
19/12/2018
13:57
Yes whatever happened to all those Japanese deals a certain person promised us....

BTW I have given £100 to the Woodland Trust which is my nominated charity since protecting the planet is the most important global concern IMHO. So that just leaves hugh to do the same to the charity of his choice since he got his calls on the company so completely and utterly wrong!

nobbygnome
19/12/2018
09:18
Interesting buying in a market devoid of it.

There was a massive buy the other day at 9.5p then the mm's shook it down to get some of the stock back at 9p and lower and once again today 2 six figure buys which are rare in this market.

As I'm long again here I hope it's insiders at work

dave4545
18/12/2018
12:17
Well actually they do have it for nothing.. they didn't pay a huge upfront fee for "first dibs" and so far haven't shown too much concern over anyone else taking it off them, even though N4 said they were "looking to add additional partnerships." Despite trawling it round Japan over 9 months ago and various trade fairs and shows there is still only one company to have shown any interest. If MedImmune decide Nuvec isn't for them N4 is hanging on by a thread, so it's a pretty tense waiting game.
dplewis1
17/12/2018
07:56
Gooood Morning. One more day closer to nanotechnology's triumph over cancer. Medimmune don't have first dibs on this for nothing you know.Go Nuvec:)))
ch1rp
14/12/2018
14:31
n4p just tweeted about moderna
remarkomsoc
Chat Pages: Latest  224  223  222  221  220  219  218  217  216  215  214  213  Older

Your Recent History

Delayed Upgrade Clock